Do you know someone who is a Canadian MPN Champion? Nominations are open for the Canadian Myeloproliferative Neoplasm Network 2017 MPN Heroes Celebration Event in Atlanta, GA, on December 8, 2017. The Canadian MPN Network will recognize one MPN hero. They may be a patient who as inspired you, a caregiver, an organization or a healthcare […]
CTI BioPharma Corp. (CTI BioPharma) announced (January 5th 2017) that the U.S. Food and Drug Administration (FDA) has lifted the full clinical hold (implemented in February 2016) on all clinical trials using the drug pacritinib. Pacritinib is a drug aimed at myelofibrosis but was placed on full clinical hold by the FDA due to safety concerns. […]
The premier hematology congress in Europe offers a program covering every subspecialty in hematology and the opportunity to network with experts from all over the globe. Educational and scientific program will highlight state-of-the art clinical practice, the latest findings in hematology research and many more interesting sessions. Objectives Hematologists and affiliated professionals attending the EHA […]
Health Canada has approved ruxolitinib (Jakavi®) for the control of hematocrit in adult patients with polycythemia vera (PV) who are resistant to or intolerant of a cytoreductive agent. Read Novartis press release
The trial drug pacritinib (in development by CTI BioPharma) has been placed on full clinical hold by the FDA due to concerns over the safety of the drug. Analysis of data from clinical trials that were ongoing show a detrimental effect on survival and patient deaths from causes including intracranial hemorrhage, cardiac failure and cardiac […]
This international conference brings together scientists and clinicians with new data on the cellular and molecular biology of these disorders as well as their diagnosis and treatment.